635 related articles for article (PubMed ID: 22682078)
21. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Nanda RH; El-Rayes B; Maithel SK; Landry J
J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
25. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Tran NH; Sahai V; Griffith KA; Nathan H; Kaza R; Cuneo KC; Shi J; Kim E; Sonnenday CJ; Cho CS; Lawrence TS; Zalupski MM
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):124-133. PubMed ID: 31494181
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA
Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
29. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Schindl M; Koelblinger C; Goetzinger P; Gnant M
World J Surg; 2011 Jul; 35(7):1580-9. PubMed ID: 21523499
[TBL] [Abstract][Full Text] [Related]
30. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant
Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
[TBL] [Abstract][Full Text] [Related]
34. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos JP; Palmer DH; Ghaneh P; Psarelli EE; Valle JW; Halloran CM; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ma YT; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Hackert T; Jackson R; Büchler MW;
Lancet; 2017 Mar; 389(10073):1011-1024. PubMed ID: 28129987
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
37. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Hewitt DB; Nissen N; Hatoum H; Musher B; Seng J; Coveler AL; Al-Rajabi R; Yeo CJ; Leiby B; Banks J; Balducci L; Vaccaro G; LoConte N; George TJ; Brenner W; Elquza E; Vahanian N; Rossi G; Kennedy E; Link C; Lavu H
Ann Surg; 2022 Jan; 275(1):45-53. PubMed ID: 33630475
[TBL] [Abstract][Full Text] [Related]
38. Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Kluger MD; Rashid MF; Rosario VL; Schrope BA; Steinman JA; Hecht EM; Chabot JA
J Gastrointest Surg; 2018 Feb; 22(2):235-241. PubMed ID: 28895032
[TBL] [Abstract][Full Text] [Related]
39. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]